The Medical Research Council (MRC) is pleased to announce a £5M call for Networks in Vaccines Research.
This call forms part of MRC’s activities under the Global Challenges Research Fund (GCRF) and therefore requires Networks to address vaccine R&D challenges primarily relevant to the health or prosperity of Low and Middle Income Countries on the Organisation for Economic Co-operation and Development (OECD) DAC List. The Networks supported through this call will contribute to the UK’s commitment to Official Development Assistance (ODA).
MRC are hosting a launch meeting and networking event on 14 October 2016 to provide potential applicants with more information about the call, the application process and opportunities to interact with others to develop Networks. The meeting is free to attend, and all interested parties must register for the meeting in advance. Following the meeting, MRC will be inviting Expressions of Interest to form Networks. Feedback will be provided to applicants and full applications invited in for assessment in March 2017.
Crimean-Congo haemorrhagic fever virus (CCHFV) is a tick borne human pathogen of the utmost seriousness being both fast acting and highly lethal - "the Asian Ebola". The virus has repeatedly caused sporadic outbreaks with a fatality rate of up to 80% yet no effective vaccines or therapeutic measures exist. Recently a "MVA-GP", pox-vectored vaccine based on Modified Vaccinia virus Ankara encoding the envelope glycoprotein (GP) spikes of CCHFV has been developed. We are seeking to recruit a post-doctoral scientist with a background in epidemiology to support a newly funded project evaluating a novel vaccine for Crimean-Congo Haemorrhagic Fever (CCHF) in collaboration with Public Health England (PHE). The successful applicant will take a leading role in designing, implementing and analyzing the results of immunogenicity and field efficacy studies in sheep. These studies will validate the vaccine as a method to control the reservoir of infection that results in human disease, analogous to the control of rabies in wild foxes in Europe. Importantly, these studies in sheep, combined with immunogenicity studies in non-human primates, will validate the vaccine platform for use in humans.
Would you like to play an active role in the UK Veterinary Vaccinology Network? Volunteer at engagement events, write blog articles on your research interests, network with other early career researchers. Email firstname.lastname@example.org